Antiseizure Drugs and Movement Disorders.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
accepted:
30
06
2022
pubmed:
22
7
2022
medline:
5
8
2022
entrez:
21
7
2022
Statut:
ppublish
Résumé
The relationship between antiseizure drugs and movement disorders is complex and not adequately reviewed so far. Antiseizure drugs as a treatment for tremor and other entities such as myoclonus and restless leg syndrome is the most common scenario, although the scientific evidence supporting their use is variable. However, antiseizure drugs also represent a potential cause of iatrogenic movement disorders, with parkinsonism and tremor the most common disorders. Many other antiseizure drug-induced movement disorders are possible and not always correctly identified. This review was conducted by searching for all the possible combinations between 15 movement disorders (excluding ataxia) and 24 antiseizure drugs. The main objective was to describe the movement disorders treated and worsened or induced by antiseizure drugs. We also summarized the proposed mechanisms and risk factors involved in the complex interaction between antiseizure drugs and movement disorders. Antiseizure drugs mainly used to treat movement disorders are clonazepam, gabapentin, lacosamide, levetiracetam, oxcarbazepine, perampanel, phenobarbital, pregabalin, primidone, topiramate, and zonisamide. Antiseizure drugs that worsen or induce movement disorders are cenobamate, ethosuximide, felbamate, lamotrigine, phenytoin, tiagabine, and vigabatrin. Antiseizure drugs with a variable effect on movement disorders are carbamazepine and valproate while no effect on movement disorders has been reported for brivaracetam, eslicarbazepine, lacosamide, and stiripentol. Although little information is available on the adverse effects or benefits on movement disorders of newer antiseizure drugs (such as brivaracetam, cenobamate, eslicarbazepine, lacosamide, and rufinamide), the evidence collected in this review should guide the choice of antiseizure drugs in patients with concomitant epilepsy and movement disorders. Finally, these notions can lead to a better understanding of the mechanisms involved in the pathophysiology and treatments of movement disorders.
Identifiants
pubmed: 35861924
doi: 10.1007/s40263-022-00937-x
pii: 10.1007/s40263-022-00937-x
doi:
Substances chimiques
Anticonvulsants
0
Levetiracetam
44YRR34555
Lacosamide
563KS2PQY5
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
859-876Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Freitas ME, Ruiz-Lopez M, Dalmau J, Erro R, Privitera M, Andrade D, et al. Seizures and movement disorders: phenomenology, diagnostic challenges and therapeutic approaches. J Neurol Neurosurg Psychiatry. 2019;90(8):920–8.
pubmed: 30796133
doi: 10.1136/jnnp-2018-320039
Spagnoli C, Fusco C, Percesepe A, Leuzzi V, Pisani F. Genetic neonatal-onset epilepsies and developmental/epileptic encephalopathies with movement disorders: a systematic review. Int J Mol Sci. 2021;22(8):4202.
pubmed: 33919646
pmcid: 8072943
doi: 10.3390/ijms22084202
Fasano A, Di Bonaventura C, Bove F, Espay AJ, Morgante F, Fabbrini G, et al. Movement disorders phenomenology in focal motor seizures. Parkinsonism Relat Disord. 2019;61:161–5.
pubmed: 30361137
doi: 10.1016/j.parkreldis.2018.10.021
de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62(1):10–5.
Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26(12):2226–31.
pubmed: 21674626
doi: 10.1002/mds.23828
Shanmugarajah PD, Hoggard N, Aeschlimann DP, Aeschlimann PC, Dennis GJ, Howell SJ, et al. Phenytoin-related ataxia in patients with epilepsy: clinical and radiological characteristics. Seizure. 2018;56:26–30.
pubmed: 29427835
doi: 10.1016/j.seizure.2018.01.019
Zaccara G, Giovannelli F, Maratea D, Fadda V, Verrotti A. Neurological adverse events of new generation sodium blocker antiepileptic drugs: meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure. 2013;22(7):528–36.
pubmed: 23623245
doi: 10.1016/j.seizure.2013.03.016
Ferner RE, Day R, Bradberry SM. Phenytoin and damage to the cerebellum: a systematic review of published cases. Expert Opin Drug Saf. 2022.
Dijk JM, Tijssen MA. Management of patients with myoclonus: available therapies and the need for an evidence-based approach. Lancet Neurol. 2010;9(10):1028–36.
pubmed: 20864054
doi: 10.1016/S1474-4422(10)70193-9
Baruzzi A, Procaccianti G, Martinelli P, Riva R, Denoth F, Montanaro N, et al. Phenobarbital and propranolol in essential tremor: a double-blind controlled clinical trial. Neurology. 1983;33(3):296–300.
pubmed: 6338416
doi: 10.1212/WNL.33.3.296
Sasso E, Perucca E, Fava R, Calzetti S. Quantitative comparison of barbiturates in essential hand and head tremor. Mov Disord. 1991;6(1):65–8.
pubmed: 2005924
doi: 10.1002/mds.870060112
Cabrera-Valdivia F, Jimenez-Jimenez FJ, Garcia Albea E, Tejeiro-Martinez J, Vaquero Ruiperez JA, Ayuso-Peralta L. Orthostatic tremor: successful treatment with phenobarbital. Clin Neuropharmacol. 1991;14(5):438–41.
pubmed: 1742753
doi: 10.1097/00002826-199110000-00008
Conte TA, Coutinho L, Teive HAG. Negative myoclonus secondary to thalamic infarction: case report. Tremor Other Hyperkinet Mov (N Y). 2021;11:25.
doi: 10.5334/tohm.629
Bobruff A, Gardos G, Tarsy D, Rapkin RM, Cole JO, Moore P. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry. 1981;138(2):189–93.
pubmed: 6109454
doi: 10.1176/ajp.138.2.189
Findley LJ, Cleeves L, Calzetti S. Primidone in essential tremor of the hands and head: a double blind controlled clinical study. J Neurol Neurosurg Psychiatry. 1985;48(9):911–5.
pubmed: 3900296
pmcid: 1028493
doi: 10.1136/jnnp.48.9.911
Poersch M. Orthostatic tremor: combined treatment with primidone and clonazepam. Mov Disord. 1994;9(4):467.
pubmed: 7969218
doi: 10.1002/mds.870090418
Scheibe F, Neumann WJ, Lange C, Scheel M, Furth C, Kohnlein M, et al. Movement disorders after hypoxic brain injury following cardiac arrest in adults. Eur J Neurol. 2020;27(10):1937–47.
pubmed: 32416613
doi: 10.1111/ene.14326
Pena AB, Caviness JN. Physiology-based treatment of myoclonus. Neurotherapeutics. 2020;17(4):1665–80.
pubmed: 32910414
pmcid: 7851206
doi: 10.1007/s13311-020-00922-6
Goldberb MA, Dorman JD. Intention myoclonus: successful treatment with clonazepam. Neurology. 1976;26(1):24–6.
pubmed: 942766
doi: 10.1212/WNL.26.1.24
Paliwal VK, Chandra S, Verma R, Kalita J, Misra UK. Clonazepam responsive opsoclonus myoclonus syndrome: additional evidence in favour of fastigial nucleus disinhibition hypothesis? J Neural Transm (Vienna). 2010;117(5):613–5.
doi: 10.1007/s00702-010-0366-y
Levy R, Plassche W, Riggs J, Shoulson I. Spinal myoclonus related to an arteriovenous malformation: response to clonazepam therapy. Arch Neurol. 1983;40(4):254–5.
pubmed: 6830478
doi: 10.1001/archneur.1983.04050040084019
Yaltho TC, Ondo WG. Orthostatic tremor: a review of 45 cases. Parkinsonism Relat Disord. 2014;20(7):723–5.
pubmed: 24736049
doi: 10.1016/j.parkreldis.2014.03.013
Hassan A, Caviness J. Slow orthostatic tremor: review of the current evidence. Tremor Other Hyperkinet Mov (N Y). 2019;9.
Bhattacharjee S. Palatal tremor: pathophysiology, clinical features, investigations, management and future challenges. Tremor Other Hyperkinet Mov (N Y). 2020;10:40.
doi: 10.5334/tohm.188
Sandyk R. Successful treatment of neuroleptic-induced akathisia with baclofen and clonazepam: a case report. Eur Neurol. 1985;24(4):286–8.
pubmed: 4006997
doi: 10.1159/000115809
Kutcher SP, Mackenzie S, Galarraga W, Szalai J. Clonazepam treatment of adolescents with neuroleptic-induced akathisia. Am J Psychiatry. 1987;144(6):823–4.
pubmed: 2884890
doi: 10.1176/ajp.144.6.823-a
Horiguchi J, Nishimatsu O, Inami Y. Successful treatment with clonazepam for neuroleptic-induced akathisia. Acta Psychiatr Scand. 1989;80(1):106–7.
pubmed: 2569804
doi: 10.1111/j.1600-0447.1989.tb01308.x
Pujalte D, Bottai T, Hue B, Alric R, Pouget R, Blayac JP, et al. A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. Clin Neuropharmacol. 1994;17(3):236–42.
pubmed: 9316669
doi: 10.1097/00002826-199406000-00003
Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2002;1:CD001950.
Thippaiah SM, Fargason RE, Birur B. Struggling to find effective pharmacologic options for akathisia? B-CALM! Psychopharmacol Bull. 2021;51(3):72–8.
pubmed: 34421146
pmcid: 8374932
Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147(4):445–51.
pubmed: 1969244
doi: 10.1176/ajp.147.4.445
Bergman H, Bhoopathi PS, Soares-Weiser K. Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1:CD000205.
Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust. 1976;1(8):225–7.
pubmed: 131236
doi: 10.5694/j.1326-5377.1976.tb140550.x
Povlsen UJ, Pakkenberg H. Effect of intravenous injection of biperiden and clonazepam in dystonia. Mov Disord. 1990;5(1):27–31.
pubmed: 2296254
doi: 10.1002/mds.870050107
Saletu A, Parapatics S, Saletu B, Anderer P, Prause W, Putz H, et al. On the pharmacotherapy of sleep bruxism: placebo-controlled polysomnographic and psychometric studies with clonazepam. Neuropsychobiology. 2005;51(4):214–25.
pubmed: 15915004
doi: 10.1159/000085917
Roshi, Tandon VR, Mahajan A, Sharma S, Khajuria V. Comparative efficacy and safety of clonazepam versus nortriptyline in restless leg syndrome among forty plus women: a prospective, open-label randomized study. J Midl Health. 2019;10(4):197–203.
Murata M, Hasegawa K, Kanazawa I; Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology. 2007;68(1):45–50.
Murata M, Hasegawa K, Kanazawa I, Fukasaka J, Kochi K, Shimazu R, et al. Zonisamide improves wearing-off in Parkinson’s disease: a randomized, double-blind study. Mov Disord. 2015;30(10):1343–50.
pubmed: 26094993
doi: 10.1002/mds.26286
Tsuboi Y, Nakamura M, Maruyama H, Matsumoto Y. Zonisamide improves wearing off in Parkinson’s disease without exacerbating dyskinesia: post hoc analysis of phase 2 and phase 3 clinical trials. J Neurol Sci. 2021;430: 120026.
pubmed: 34715471
doi: 10.1016/j.jns.2021.120026
Murata M, Odawara T, Hasegawa K, Iiyama S, Nakamura M, Tagawa M, et al. Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized double-blind phase 2 study. Neurology. 2018;90(8):e664–72.
pubmed: 29367449
pmcid: 5818167
doi: 10.1212/WNL.0000000000005010
Hainque E, Vidailhet M, Cozic N, Charbonnier-Beaupel F, Thobois S, Tranchant C, et al. A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. Neurology. 2016;86(18):1729–35.
pubmed: 27053715
doi: 10.1212/WNL.0000000000002631
Egel RT, Hoganson GE, Katerji MA, Borenstein MJ. Zonisamide ameliorates symptoms of secondary paroxysmal dystonia. Pediatr Neurol. 2010;43(3):205–8.
pubmed: 20691944
doi: 10.1016/j.pediatrneurol.2010.04.008
Matsuura R, Hamano SI, Hiwatari E, Ikemoto S, Hirata Y, Koichihara R, et al. Zonisamide therapy for patients with paroxysmal kinesigenic dyskinesia. Pediatr Neurol. 2020;111:23–6.
pubmed: 32951651
doi: 10.1016/j.pediatrneurol.2020.06.017
Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002;59(10):1573–9.
pubmed: 12451200
doi: 10.1212/WNL.59.10.1573
Zhou X, Du J, Liang Y, Dai C, Zhao L, Liu X, et al. The efficacy and safety of pharmacological treatments for restless legs syndrome: systemic review and network meta-analysis. Front Neurosci. 2021;15: 751643.
pubmed: 34764852
pmcid: 8576256
doi: 10.3389/fnins.2021.751643
Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000;15(4):678–82.
pubmed: 10928578
doi: 10.1002/1531-8257(200007)15:4<678::AID-MDS1012>3.0.CO;2-0
Onofrj M, Thomas A, Paci C, D’Andreamatteo G. Gabapentin in orthostatic tremor: results of a double-blind crossover with placebo in four patients. Neurology. 1998;51(3):880–2.
pubmed: 9748048
doi: 10.1212/WNL.51.3.880
Connor GS, Edwards K, Tarsy D. Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials. Clin Neuropharmacol. 2008;31(2):97–103.
pubmed: 18382182
doi: 10.1097/WNF.0b013e3180d09969
Kobylecki C, Marshall AG, Varma A, Kellett MW, Dick JP, Silverdale MA. Topiramate-responsive cerebellar axial postural tremor. Mov Disord. 2008;23(8):1189–91.
pubmed: 18442113
doi: 10.1002/mds.22068
Gatto EM, Uribe Roca C, Raina G, Gorja M, Folgar S, Micheli FE. Vascular hemichorea/hemiballism and topiramate. Mov Disord. 2004;19(7):836–8.
pubmed: 15254947
doi: 10.1002/mds.20086
Huang YG, Chen YC, Du F, Li R, Xu GL, Jiang W, et al. Topiramate therapy for paroxysmal kinesigenic choreoathetosis. Mov Disord. 2005;20(1):75–7.
pubmed: 15390133
doi: 10.1002/mds.20283
Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81(1):70–3.
pubmed: 19726418
doi: 10.1136/jnnp.2009.185348
Pringsheim T, Holler-Managan Y, Okun MS, Jankovic J, Piacentini J, Cavanna AE, et al. Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):907–15.
pubmed: 31061209
pmcid: 6537130
doi: 10.1212/WNL.0000000000007467
Yang Y, Su Y, Guo Y, Ding Y, Xu S, Jiang Y, et al. Oxcarbazepine versus carbamazepine in the treatment of paroxysmal kinesigenic dyskinesia. Int J Neurosci. 2012;122(12):719–22.
pubmed: 22856516
doi: 10.3109/00207454.2012.715109
Kumar A, Szekely A, Jabbari B. Effective treatment of paroxysmal nonkinesigenic dyskinesia with oxcarbazepine. Clin Neuropharmacol. 2016;39(4):201–5.
pubmed: 27046658
doi: 10.1097/WNF.0000000000000149
Jimenez-Trevino L. Oxcarbazepine treatment of restless legs syndrome: three case reports. Clin Neuropharmacol. 2009;32(3):169–70.
pubmed: 19483488
doi: 10.1097/WNF.0b013e31818f1125
Krauss GL, Bergin A, Kramer RE, Cho YW, Reich SG. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology. 2001;56(3):411–2.
pubmed: 11171914
doi: 10.1212/WNL.56.3.411
Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology. 2001;57(6):1112–4.
pubmed: 11571347
doi: 10.1212/WNL.57.6.1112
Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69(4):546–54.
pubmed: 18312060
doi: 10.4088/JCP.v69n0405
Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord. 2006;21(8):1219–21.
pubmed: 16637037
doi: 10.1002/mds.20835
Garcia-Borreguero D, Larrosa O, Williams AM, Albares J, Pascual M, Palacios JC, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology. 2010;74(23):1897–904.
pubmed: 20427750
doi: 10.1212/WNL.0b013e3181e1ce73
Zesiewicz TA, Ward CL, Hauser RA, Salemi JL, Siraj S, Wilson MC, et al. A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord. 2007;22(11):1660–3.
pubmed: 17580330
doi: 10.1002/mds.21629
Ferrara JM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci. 2009;285(1–2):195–7.
pubmed: 19631949
doi: 10.1016/j.jns.2009.06.044
Mathew T, Aroor S, Nadig R, Sarma GR. Lacosamide in paroxysmal kinesigenic dyskinesia. Mov Disord. 2012;27(6):801–2.
pubmed: 22290793
doi: 10.1002/mds.24928
Furukawa G, Negishi Y, Takeuchi T, Ishihara N, Okumura A. Lacosamide for children with paroxysmal kinesigenic dyskinesia. Brain Dev. 2020;42(8):617–20.
pubmed: 32430160
doi: 10.1016/j.braindev.2020.04.009
Geng JH, Zheng Y, Li QF, Hou Q, Wang XH, Jiang Y. Case report: a case of concomitant paroxysmal kinesigenic dyskinesia and epilepsy: can we treat two birds with one stone? Front Neurol. 2022;13: 826897.
pubmed: 35185774
pmcid: 8847266
doi: 10.3389/fneur.2022.826897
Galldiks N, Timmermann L, Fink GR, Burghaus L. Posthypoxic myoclonus (Lance-Adams syndrome) treated with lacosamide. Clin Neuropharmacol. 2010;33(4):216–7.
pubmed: 20661030
doi: 10.1097/WNF.0b013e3181e1613f
Salari M, Asadi S, Etemadifar M, Rezaee M. Myoclonic dystonia (DYT11) responsive to lacosamide: a case report. Acta Neurol Belg. 2021.
Ruiz-Julian M, Orozco JL, Gironell A. Complete resolution of symptoms of primary orthostatic tremor with perampanel. Tremor Other Hyperkinet Mov (N Y). 2018;8:552.
doi: 10.5334/tohm.414
Wadhwa A, Schaefer SM. Successful treatment of primary orthostatic tremor using perampanel. Tremor Other Hyperkinet Mov (N Y). 2019;9.
Gironell A, Marin-Lahoz J. Primary orthostatic tremor: experience of perampanel use in 20 patients. Tremor Other Hyperkinet Mov (N Y). 2019;9.
Handforth A, Tse W, Elble RJ. A pilot double-blind randomized trial of perampanel for essential tremor. Mov Disord Clin Pract. 2020;7(4):399–404.
pubmed: 32373656
pmcid: 7197304
doi: 10.1002/mdc3.12927
Gironell A, Pascual-Sedano B, Marin-Lahoz J. Perampanel, a new hope for essential tremor: an open label trial. Parkinsonism Relat Disord. 2019;60:171–2.
pubmed: 30318448
doi: 10.1016/j.parkreldis.2018.10.010
Garcia-Borreguero D, Cano I, Granizo JJ. Treatment of restless legs syndrome with the selective AMPA receptor antagonist perampanel. Sleep Med. 2017;34:105–8.
pubmed: 28522077
doi: 10.1016/j.sleep.2017.03.012
Steinhoff BJ, Bacher M, Kurth C, Staack AM, Kornmeier R. Add-on perampanel in Lance-Adams syndrome. Epilepsy Behav Case Rep. 2016;6:28–9.
pubmed: 27437182
pmcid: 4939387
doi: 10.1016/j.ebcr.2016.05.001
Kamel WA, Al-Hashel JY, Abdulsalam AJ, Arabi M. Perampanel in refractory post-hypoxic myoclonus: see the difference! Acta Neurol Belg. 2020;120(3):741–2.
pubmed: 31848939
doi: 10.1007/s13760-019-01259-4
Duarte J, Sempere AP, Cabezas MC, Marcos J, Claveria LE. Postural myoclonus induced by phenytoin. Clin Neuropharmacol. 1996;19(6):536–8.
pubmed: 8937794
doi: 10.1097/00002826-199619060-00009
Chi WM, Chua KS, Kong KH. Phenytoin-induced asterixis: uncommon or under-diagnozed? Brain Inj. 2000;14(9):847–50.
pubmed: 11030457
doi: 10.1080/026990500421949
Chalhub EG, Devivo DC, Volpe JJ. Phenytoin-induced dystonia and choreoathetosis in two retarded epileptic children. Neurology. 1976;26(5):494–8.
pubmed: 944401
doi: 10.1212/WNL.26.5.494
Patel DM, Gurumukhani JK, Patel MV, Patel GR. Phenytoin induced chorea: a rare adverse effect of the drug. Curr Drug Saf. 2019;14(1):51–2.
pubmed: 30381086
doi: 10.2174/1574886313666181031161215
Shulman LM, Singer C, Weiner WJ. Phenytoin-induced focal chorea. Mov Disord. 1996;11(1):111–4.
pubmed: 8771085
doi: 10.1002/mds.870110128
Lucey BP. Teaching video neuroImages: phenytoin-induced orofacial dyskinesias. Neurology. 2012;79(19): e177.
pubmed: 23128448
doi: 10.1212/WNL.0b013e3182735eac
Nausieda PA, Koller WC, Klawans HL, Weiner WJ. Phenytoin and choreic movements. N Engl J Med. 1978;298(19):1093–4.
pubmed: 643025
doi: 10.1056/NEJM197805112981923
Acar T, Alkan G, Caksen H, Ertekin B, Ergin M, Kocak S, et al. Phenytoin induced dystonia. Turk J Pediatr. 2018;60(1):111–2.
pubmed: 30102491
doi: 10.24953/turkjped.2018.01.019
Goni M, Jimenez M, Feijoo M. Parkinsonism induced by phenytoin. Clin Neuropharmacol. 1985;8(4):383–4.
pubmed: 4075309
doi: 10.1097/00002826-198512000-00012
Ertan S, Ulu MO, Hanimoglu H, Tanriverdi T, Kafadar AM, Acar ZU, et al. Phenytoin-induced parkinsonism. Singapore Med J. 2006;47(11):981–3.
pubmed: 17075669
Mendez JS, Cotzias GC, Mena I, Papavasiliou PS. Diphenylhydantoin: blocking of levodopa effects. Arch Neurol. 1975;32(1):44–6.
pubmed: 123156
doi: 10.1001/archneur.1975.00490430066011
Kirschberg GJ. Dyskinesia: an unusual reaction to ethosuximide. Arch Neurol. 1975;32(2):137–8.
pubmed: 804894
doi: 10.1001/archneur.1975.00490440087017
Ehyai A, Kilroy AW, Fenichel GM. Dyskinesia and akathisia induced by ethosuximide. Am J Dis Child. 1978;132(5):527–8.
pubmed: 645680
Abou-Khalil BW. Update on antiepileptic drugs 2019. Continuum (Minneap Minn). 2019;25(2):508–36.
pubmed: 30921021
Neufeld MY, Vishnevska S. Vigabatrin and multifocal myoclonus in adults with partial seizures. Clin Neuropharmacol. 1995;18(3):280–3.
pubmed: 8635188
doi: 10.1097/00002826-199506000-00010
Tombini M, Pellegrino G, Assenza G, Di Lazzaro V. De novo multifocal myoclonus induced by lamotrigine in a temporal lobe epilepsy case. J Neurol Sci. 2017;373:31–2.
pubmed: 28131212
doi: 10.1016/j.jns.2016.12.022
Fernandez Corcuera P, Pomarol E, Amann B, McKenna P. Myoclonus provoked by lamotrigine in a bipolar patient. J Clin Psychopharmacol. 2008;28(2):248–9.
pubmed: 18344744
doi: 10.1097/JCP.0b013e318167465f
He ZF, Chen J, Zhou CN, Rao Z, Wang XH. Disabling tremor induced by long-term use of sodium valproate and lamotrigine: case report. Medicine (Baltimore). 2017;96(47): e8711.
doi: 10.1097/MD.0000000000008711
Yang JH, Chung SW, Kim JS. Action tremor associated with lamotrigine monotherapy. J Mov Disord. 2010;3(1):18–9.
pubmed: 24868374
pmcid: 4027652
doi: 10.14802/jmd.10005
Zaatreh M, Tennison M, D’Cruz O, Beach RL. Anticonvulsants-induced chorea: a role for pharmacodynamic drug interaction? Seizure. 2001;10(8):596–9.
pubmed: 11792164
doi: 10.1053/seiz.2001.0555
Das KB, Harris C, Smyth DP, Cross JH. Unusual side effects of lamotrigine therapy. J Child Neurol. 2003;18(7):479–80.
pubmed: 12940653
doi: 10.1177/08830738030180070301
Miller MA, Levsky ME. Choreiform dyskinesia following isolated lamotrigine overdose. J Child Neurol. 2008;23(2):243.
pubmed: 18263762
doi: 10.1177/0883073807308693
Santens P, Claeys I, Vonck K, Boon P. Parkinsonism due to lamotrigine. Mov Disord. 2006;21(12):2269–70.
pubmed: 17013910
doi: 10.1002/mds.21125
Sabolek M, Runge U. Lamotrigine induced dyskinesia in Parkinson’s disease. Eur J Neurol. 2010;17(5): e37.
pubmed: 20236309
doi: 10.1111/j.1468-1331.2010.02981.x
Shinotoh H, Vingerhoets FJ, Lee CS, Uitti RJ, Schulzer M, Calne DB, et al. Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study. Neurology. 1997;48(5):1282–5.
pubmed: 9153458
doi: 10.1212/WNL.48.5.1282
Musiek ES, Anderson CT, Dahodwala NA, Pollard JR. Facial tic associated with lamotrigine in adults. Mov Disord. 2010;25(10):1512–3.
pubmed: 20629145
doi: 10.1002/mds.23120
Rissardo JP, Fornari Caprara AL. Lamotrigine-associated movement disorder: a literature review. Neurol India. 2021;69(6):1524–38.
pubmed: 34979637
doi: 10.4103/0028-3886.333440
Sotero de Menezes MA, Rho JM, Murphy P, Cheyette S. Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia. 2000;41(7):862–7.
Alkin T, Onur E, Ozerdem A. Co-occurence of blepharospasm, tourettism and obsessive-compulsive symptoms during lamotrigine treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1339–40.
pubmed: 17537560
doi: 10.1016/j.pnpbp.2007.04.015
Veerapandiyan A, Gallentine WB, Winchester SA, Baker J, Kansagra SM, Mikati MA. Oculogyric crises secondary to lamotrigine overdosage. Epilepsia. 2011;52(3):e4-6.
pubmed: 21395567
doi: 10.1111/j.1528-1167.2010.02967.x
Kerrick JM, Kelley BJ, Maister BH, Graves NM, Leppik IE. Involuntary movement disorders associated with felbamate. Neurology. 1995;45(1):185–7.
pubmed: 7824115
doi: 10.1212/WNL.45.1.185
Gironell A, Martinez-Corral M, Pagonabarraga X, Kulisevsky J. Tiagabine for essential tremor: an open-label trial. Mov Disord. 2008;23(13):1955–6.
pubmed: 18759354
doi: 10.1002/mds.22094
Zesiewicz TA, Sullivan KL, Ward CL, Hauser RA. Tiagabine and exacerbation of essential tremor. Mov Disord. 2007;22(14):2132–3.
pubmed: 17663461
doi: 10.1002/mds.21559
Leppik IE. Tiagabine: the safety landscape. Epilepsia. 1995;36(Suppl. 6):S10–3.
pubmed: 8595787
doi: 10.1111/j.1528-1157.1995.tb06009.x
Wolanczyk T, Grabowska-Grzyb A. Transient dystonias in three patients treated with tiagabine. Epilepsia. 2001;42(7):944–6.
pubmed: 11488897
doi: 10.1046/j.1528-1157.2001.042007944.x
Tombini M, Pacifici L, Passarelli F, Rossini PM. Transient athetosis induced by tiagabine. Epilepsia. 2006;47(4):799–800.
pubmed: 16650148
doi: 10.1111/j.1528-1167.2006.00530.x
Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311–22.
pubmed: 32409485
pmcid: 7357293
doi: 10.1212/WNL.0000000000009530
Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099–108.
pubmed: 32396252
pmcid: 7317552
doi: 10.1111/epi.16525
Rissardo JP, Caprara ALF. Carbamazepine-, oxcarbazepine-, eslicarbazepine-associated movement disorder: a literature review. Clin Neuropharmacol. 2020;43(3):66–80.
pubmed: 32384309
doi: 10.1097/WNF.0000000000000387
Dhuna A, Pascual-Leone A, Talwar D. Exacerbation of partial seizures and onset of nonepileptic myoclonus with carbamazepine. Epilepsia. 1991;32(2):275–8.
pubmed: 1900790
doi: 10.1111/j.1528-1157.1991.tb05255.x
Magaudda A, Di Rosa G. Carbamazepine-induced non-epileptic myoclonus and tic-like movements. Epileptic Disord. 2012;14(2):172–3.
pubmed: 22584239
doi: 10.1684/epd.2012.0504
Kurlan R, Kersun J, Behr J, Leibovici A, Tariot P, Lichter D, et al. Carbamazepine-induced tics. Clin Neuropharmacol. 1989;12(4):298–302.
pubmed: 2529963
doi: 10.1097/00002826-198908000-00007
Robertson PL, Garofalo EA, Silverstein FS, Komarynski MA. Carbamazepine-induced tics. Epilepsia. 1993;34(5):965–8.
pubmed: 8404753
doi: 10.1111/j.1528-1157.1993.tb02119.x
Stryjer R, Strous RD, Bar F, Ulman AM, Rabey JM. Segmental dystonia as the sole manifestation of carbamazepine toxicity. Gen Hosp Psychiatry. 2002;24(2):114–5.
pubmed: 11869747
doi: 10.1016/S0163-8343(01)00177-3
Bansal S, Gill M, Bhasin C. Carbamazepine-induced dystonia in an adolescent. Indian J Pharmacol. 2016;48(3):329–30.
pubmed: 27298509
pmcid: 4900012
doi: 10.4103/0253-7613.182879
Lazarus A. Tardive dyskinesia-like syndrome associated with lithium and carbamazepine. J Clin Psychopharmacol. 1994;14(2):146–7.
pubmed: 8195458
doi: 10.1097/00004714-199404000-00012
Bimpong-Buta K, Froescher W. Carbamazepine-induced choreoathetoid dyskinesias. J Neurol Neurosurg Psychiatry. 1982;45(6):560.
pubmed: 6811702
pmcid: 491437
doi: 10.1136/jnnp.45.6.560
Montilla-Uzcategui V, Araujo-Unda H, Daza-Restrepo A, Saenz-Farret M, Micheli F. Paroxysmal nonkinesigenic dyskinesias responsive to carbamazepine in Fahr syndrome: a case report. Clin Neuropharmacol. 2016;39(5):262–4.
pubmed: 27280699
doi: 10.1097/WNF.0000000000000164
Lundvall O, Abom PE, Holm R. Carbamazepine in restless legs: a controlled pilot study. Eur J Clin Pharmacol. 1983;25(3):323–4.
pubmed: 6354728
doi: 10.1007/BF01037942
Genel F, Arslanoglu S, Uran N, Saylan B. Sydenham’s chorea: clinical findings and comparison of the efficacies of sodium valproate and carbamazepine regimens. Brain Dev. 2002;24(2):73–6.
pubmed: 11891095
doi: 10.1016/S0387-7604(01)00404-1
Brugger F, Bhatia KP, Besag FM. Valproate-associated parkinsonism: a critical review of the literature. CNS Drugs. 2016;30(6):527–40.
pubmed: 27255404
doi: 10.1007/s40263-016-0341-8
Alvarez-Gomez MJ, Vaamonde J, Narbona J, Barao M, Barona P, Brannan T, et al. Parkinsonian syndrome in childhood after sodium valproate administration. Clin Neuropharmacol. 1993;16(5):451–5.
pubmed: 8221706
doi: 10.1097/00002826-199310000-00009
Ristic AJ, Vojvodic N, Jankovic S, Sindelic A, Sokic D. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia. 2006;47(12):2183–5.
pubmed: 17201721
doi: 10.1111/j.1528-1167.2006.00711.x
Masmoudi K, Gras-Champel V, Masson H, Andrejak M. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry. 2006;39(1):9–12.
pubmed: 16453247
doi: 10.1055/s-2006-931471
Mehndiratta MM, Satyawani M, Gupta S, Khwaja GA. Clinical and surface EMG characteristics of valproate induced tremors. Electromyogr Clin Neurophysiol. 2005;45(3):177–82.
pubmed: 15981690
Gupta A, Kushwaha S. Disabling resting tremors induced by the short-term infusion of valproate: a reversible phenomenon. Tremor Other Hyperkinet Mov (N Y). 2018;8:615.
doi: 10.5334/tohm.424
Rinnerthaler M, Luef G, Mueller J, Seppi K, Wissel J, Trinka E, et al. Computerized tremor analysis of valproate-induced tremor: a comparative study of controlled-release versus conventional valproate. Epilepsia. 2005;46(2):320–3.
pubmed: 15679514
doi: 10.1111/j.0013-9580.2005.36204.x
Alonso-Juarez M, Torres-Russotto D, Crespo-Morfin P, Baizabal-Carvallo JF. The clinical features and functional impact of valproate-induced tremor. Parkinsonism Relat Disord. 2017;44:147–50.
pubmed: 28941829
doi: 10.1016/j.parkreldis.2017.09.011
Nasr Esfahani P, Nasiri J, Badihian S, Yaghini O. Short-term side effects of low dose valproate monotherapy in epileptic children: a prospective study. Iran J Child Neurol. 2019;13(2):37–46.
pubmed: 31037076
pmcid: 6451855
Chandra V, Spunt AL, Rusinowitz MS. Treatment of post-traumatic choreo-athetosis with sodium valproate. J Neurol Neurosurg Psychiatry. 1983;46(10):963.
pubmed: 6417281
pmcid: 1027613
doi: 10.1136/jnnp.46.10.963
Hoffman AS, Feinberg TE. Successful treatment of age-related chorea with sodium valproate. J Am Geriatr Soc. 1990;38(1):56–8.
pubmed: 2104885
doi: 10.1111/j.1532-5415.1990.tb01598.x
Lenton RJ, Copti M, Smith RG. Hemiballismus treated with sodium valproate. Br Med J (Clin Res Ed). 1981;283(6283):17–8.
doi: 10.1136/bmj.283.6283.17
McLachlan RS. Valproic acid in Sydenham’s chorea. Br Med J (Clin Res Ed). 1981;283(6286):274–5.
doi: 10.1136/bmj.283.6286.274
Dhanaraj M, Radhakrishnan AR, Srinivas K, Sayeed ZA. Sodium valproate in Sydenham’s chorea. Neurology. 1985;35(1):114–5.
pubmed: 3917559
doi: 10.1212/WNL.35.1.114
Rissardo JP, Caprara ALF, Durante I. Valproate-associated movement disorder: a literature review. Prague Med Rep. 2021;122(3):140–80.
pubmed: 34606429
doi: 10.14712/23362936.2021.14
Habermeyer B, Rabovsky K, Jentzsch C, Pinhard K, Muller-Spahn F. Cervical dystonia due to interaction of valproic acid and quetiapine. J Clin Psychopharmacol. 2007;27(4):396–7.
pubmed: 17632227
doi: 10.1097/01.jcp.0000264989.63227.82
Fahn S. Post-anoxic action myoclonus: improvement with valproic acid. N Engl J Med. 1978;299(6):313–4.
pubmed: 351404
Caviness JN. Treatment of myoclonus. Neurotherapeutics. 2014;11(1):188–200.
pubmed: 24037428
doi: 10.1007/s13311-013-0216-3
Ye L, Lippmann S. Tourette disorder treated with valproic acid. Clin Neuropharmacol. 2014;37(1):36–7.
pubmed: 24434532
doi: 10.1097/WNF.0000000000000013
Brennan MJ, Ruff P, Sandyk R. Efficacy of a combination of sodium valproate and baclofen in Meige’s disease (idiopathic orofacial dystonia). Br Med J (Clin Res Ed). 1982;285(6345):853.
doi: 10.1136/bmj.285.6345.853
Borggreve F, Hageman G. A case of idiopathic palatal myoclonus: treatment with sodium valproate. Eur Neurol. 1991;31(6):403–4.
pubmed: 1756767
doi: 10.1159/000116704
Serrano-Duenas M. Use of primidone in low doses (250 mg/day) versus high doses (750 mg/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up. Parkinsonism Relat Disord. 2003;10(1):29–33.
Turjanski N, Lees AJ. Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1992;55(5):413.
pubmed: 1602321
pmcid: 489093
doi: 10.1136/jnnp.55.5.413
Korsgaard S, Casey DE, Gerlach J. Effect of gamma-vinyl GABA in tardive dyskinesia. Psychiatry Res. 1983;8(4):261–9.
pubmed: 6136054
doi: 10.1016/0165-1781(83)90014-8
Sethi KD, Hitri A, Diamond BI. Phenytoin potentiation of neuroleptic-induced dyskinesias. Mov Disord. 1990;5(4):325–7.
pubmed: 2147979
doi: 10.1002/mds.870050413
Happe S, Klosch G, Saletu B, Zeitlhofer J. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology. 2001;57(9):1717–9.
pubmed: 11706121
doi: 10.1212/WNL.57.9.1717
Jamora D, Lim SH, Pan A, Tan L, Tan EK. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord. 2007;22(1):130–3.
pubmed: 17115396
doi: 10.1002/mds.21188
Weiner WJ, Nausieda PA, Glantz RH. Meige syndrome (blepharospasm-oromandibular dystonia) after long-term neuroleptic therapy. Neurology. 1981;31(12):1555–6.
pubmed: 6118844
doi: 10.1212/WNL.31.12.1555
Masui T, Kusumi I, Takahashi Y, Koyama T. Efficacy of carbamazepine against neuroleptic-induced akathisia in treatment with perospirone: case series. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(2):343–6.
pubmed: 15694245
doi: 10.1016/j.pnpbp.2004.11.022
Harel L, Zecharia A, Straussberg R, Volovitz B, Amir J. Successful treatment of rheumatic chorea with carbamazepine. Pediatr Neurol. 2000;23(2):147–51.
pubmed: 11020640
doi: 10.1016/S0887-8994(00)00177-6
Garg BP. Dystonia musculorum deformans: implications of therapeutic response to levodopa and carbamazepine. Arch Neurol. 1982;39(6):376–7.
pubmed: 7092616
doi: 10.1001/archneur.1982.00510180054014
Harmon RL, Long DF, Shirtz J. Treatment of post-traumatic midbrain resting-kinetic tremor with combined levodopa/carbidopa and carbamazepine. Brain Inj. 1991;5(2):213–8.
pubmed: 1873607
doi: 10.3109/02699059109008092
Loeb C, Priano A. Preliminary evaluation of the effects of clonazepam on parkinsonian tremor. Eur Neurol. 1977;15(3):143–5.
pubmed: 852470
doi: 10.1159/000114803
Gillman MA, Sandyk R. Clonazepam-induced Tourette syndrome in a subject with hyperexplexia. Postgrad Med J. 1987;63(738):311–2.
pubmed: 3479756
pmcid: 2428168
doi: 10.1136/pgmj.63.738.311-a
Steingard RJ, Goldberg M, Lee D, DeMaso DR. Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. J Am Acad Child Adolesc Psychiatry. 1994;33(3):394–9.
pubmed: 8169185
doi: 10.1097/00004583-199403000-00014
Biary N, Koller W. Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology. 1987;37(3):471–4.
pubmed: 3822141
doi: 10.1212/WNL.37.3.471
Jacob PC, Pratap CR. Posttraumatic rubral tremor responsive to clonazepam. Mov Disord. 1998;13(6):977–8.
pubmed: 9827628
doi: 10.1002/mds.870130622
Edwards KR. Felbamate and tremor. Neurology. 1995;45(10):1951.
pubmed: 7478012
doi: 10.1212/WNL.45.10.1951
See S, Hendriks E, Hsiung L. Akathisia induced by gabapentin withdrawal. Ann Pharmacother. 2011;45(6): e31.
pubmed: 21652784
doi: 10.1345/aph.1Q057
Madani AS, Abdollahian E, Khiavi HA, Radvar M, Foroughipour M, Asadpour H, et al. The efficacy of gabapentin versus stabilization splint in management of sleep bruxism. J Prosthodont. 2013;22(2):126–31.
pubmed: 22946979
doi: 10.1111/j.1532-849X.2012.00914.x
Zesiewicz TA, Shimberg WR, Hauser RA, Robinson W, Wilson MC, Sullivan KL. Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome type 1. Clin Rheumatol. 2008;27(3):389–90.
pubmed: 17938990
doi: 10.1007/s10067-007-0744-5
Asconape J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia. 2000;41(4):479–81.
pubmed: 10756416
doi: 10.1111/j.1528-1157.2000.tb00192.x
Olson WL, Gruenthal M, Mueller ME, Olson WH. Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Am J Med. 1997;102(1):60–6.
pubmed: 9209202
doi: 10.1016/S0002-9343(96)00381-6
Shen YC. Lamotrigine in motor and mood symptoms of Huntington’s disease. World J Biol Psychiatry. 2008;9(2):147–9.
pubmed: 17853293
doi: 10.1080/15622970701332520
Li F, Lin ZD, Hu Y, Li W, Xue CC, Poonit ND. Lamotrigine monotherapy for paroxysmal kinesigenic dyskinesia in children. Seizure. 2016;37:41–4.
pubmed: 26987034
doi: 10.1016/j.seizure.2016.02.009
Youssef EA, Wagner ML, Martinez JO, Hening W. Pilot trial of lamotrigine in the restless legs syndrome. Sleep Med. 2005;6(1):89.
pubmed: 15680305
doi: 10.1016/j.sleep.2004.10.009
Mendhekar DN, Duggal HS. Acquired variant of Rett’s disorder and response to lamotrigine. J Neuropsychiatry Clin Neurosci. 2007;19(4):474–5.
pubmed: 18070858
doi: 10.1176/jnp.2007.19.4.474
Ortiz A, Alda M, O’Donovan C. Tourette syndrome with comorbid bipolar disorder and migraine: can lamotrigine monotherapy help? J Clin Psychopharmacol. 2012;32(1):140–2.
pubmed: 22217952
doi: 10.1097/JCP.0b013e31823fa929
Zesiewicz TA, Sullivan KL, Hauser RA, Sanchez-Ramos J. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington’s disease. Mov Disord. 2006;21(11):1998–2001.
pubmed: 16941461
doi: 10.1002/mds.21061
Alemdar M, Iseri P, Selekler M, Komsuoglu SS. Levetiracetam-responding paroxysmal nonkinesigenic dyskinesia. Clin Neuropharmacol. 2007;30(4):241–4.
pubmed: 17762321
doi: 10.1097/wnf.0b013e31803b9415
Zesiewicz TA, Louis ED, Sullivan KL, Menkin M, Dunne PB, Hauser RA. Substantial improvement in a Meige’s syndrome patient with levetiracetam treatment. Mov Disord. 2004;19(12):1518–21.
pubmed: 15390069
doi: 10.1002/mds.20233
Zesiewicz TA, Sanchez-Ramos J, Sullivan KL, Hauser RA. Levetiracetam-induced parkinsonism in a Huntington disease patient. Clin Neuropharmacol. 2005;28(4):188–90.
pubmed: 16062099
doi: 10.1097/01.wnf.0000169732.00690.32
Gagliano A, Arico I, Calarese T, Condurso R, Germano E, Cedro C, et al. Restless leg syndrome in ADHD children: levetiracetam as a reasonable therapeutic option. Brain Dev. 2011;33(6):480–6.
pubmed: 20950971
doi: 10.1016/j.braindev.2010.09.008
Fernandez-Jaen A, Fernandez-Mayoralas DM, Munoz-Jareno N, Calleja-Perez B. An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome. Eur J Paediatr Neurol. 2009;13(6):541–5.
pubmed: 19211282
doi: 10.1016/j.ejpn.2008.12.006
Feys P, D’Hooghe MB, Nagels G, Helsen WF. The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. Mult Scler. 2009;15(3):371–8.
pubmed: 19168602
doi: 10.1177/1352458508099142
Okuyucu EE, Duman T, Akcin E. Reversible parkinsonism with oxcarbazepine use. Parkinsonism Relat Disord. 2009;15(10):787–8.
pubmed: 19401271
doi: 10.1016/j.parkreldis.2009.03.007
Lacayo A, Mitra N. Report of a case of phenobarbital-induced dystonia. Clin Pediatr (Phila). 1992;31(4):252.
doi: 10.1177/000992289203100413
Sandyk R. Phenobarbital-induced Tourette-like symptoms. Pediatr Neurol. 1986;2(1):54–5.
pubmed: 3150278
doi: 10.1016/0887-8994(86)90042-1
Bonakis A, Papageorgiou SG, Potagas C, Karahalios G, Kalfakis N. A case of refractory secondary paroxysmal kinesigenic dyskinesia with high sensitivity to phenytoin monotherapy. Parkinsonism Relat Disord. 2009;15(1):68–70.
pubmed: 18353702
doi: 10.1016/j.parkreldis.2008.01.015
Dag E, Gokce B, Buturak SV, Tiryaki D, Erdemoglu AK. Pregabalin-induced akathisia. Ann Pharmacother. 2013;47(4):592–3.
pubmed: 23535811
doi: 10.1345/aph.1R699
Baek WS. Pregabalin resolves refractory aparathyroid paroxysmal kinesigenic choreoathetosis. Clin Neuropharmacol. 2012;35(4):203.
pubmed: 22805232
doi: 10.1097/WNF.0b013e31825bd3d7
Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia. 2001;42(6):790–2.
pubmed: 11422338
doi: 10.1046/j.1528-1157.2001.44000.x
Perez Lloret S, Amaya M, Merello M. Pregabalin-induced parkinsonism: a case report. Clin Neuropharmacol. 2009;32(6):353–4.
pubmed: 19952879
doi: 10.1097/WNF.0b013e3181a9eb1b
Coltamai L, Magezi DA, Croquelois A. Pregabalin in the treatment of neuropathic tremor following a motor axonal form of Guillain-Barre syndrome. Mov Disord. 2010;25(4):517–9.
pubmed: 20108360
doi: 10.1002/mds.22961
van der Zwan A, Verwey JC, van Gijn J. Relief of orthostatic tremor by primidone. Neurology. 1988;38(8):1332.
pubmed: 3399088
doi: 10.1212/WNL.38.8.1332
Kast RE. Tiagabine may reduce bruxism and associated temporomandibular joint pain. Anesth Prog. 2005;52(3):102–4.
pubmed: 16252740
pmcid: 1586785
doi: 10.2344/0003-3006(2005)52[102:TMRBAA]2.0.CO;2
Mowla A, Sabayan B. Topiramate for bruxism: report of 2 cases. J Clin Psychopharmacol. 2010;30(3):346–7.
pubmed: 20473082
doi: 10.1097/JCP.0b013e3181dbfc0b
Papapetropoulos S, Singer C. Improvement of cervico-trunco-brachial segmental dystonia with topiramate. J Neurol. 2006;253(4):535–6.
pubmed: 16328112
doi: 10.1007/s00415-005-0029-3
Miller AD, Prost VM, Bookstaver PB, Gaines KJ. Topiramate-induced myoclonus and psychosis during migraine prophylaxis. Am J Health Syst Pharm. 2010;67(14):1178–80.
pubmed: 20592323
doi: 10.2146/ajhp090185
Siniscalchi A, Mancuso F, Russo E, Ibbadu GF, De Sarro G. Spinal myoclonus responsive to topiramate. Mov Disord. 2004;19(11):1380–1.
pubmed: 15389982
doi: 10.1002/mds.20217
Bermejo PE. Restless legs syndrome induced by topiramate: two more cases. J Neurol. 2009;256(4):662–3.
pubmed: 19444538
doi: 10.1007/s00415-009-0073-5
Srinivasan S, Lok AW. Valproate-induced reversible hemichorea. Mov Disord. 2010;25(10):1511–2.
pubmed: 20629154
doi: 10.1002/mds.23119
Linnoila M, Viukari M, Kietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry. 1976;129:114–9.
pubmed: 786416
doi: 10.1192/bjp.129.2.114
Tao D, Zhong T, Ma S, Li J, Li X. Randomized controlled clinical trial comparing the efficacy and tolerability of aripiprazole and sodium valproate in the treatment of Tourette syndrome. Ann Gen Psychiatry. 2019;18:24.
pubmed: 31624488
pmcid: 6785853
doi: 10.1186/s12991-019-0245-3
Leuzzi V, Di Sabato ML, Deodato F, Rizzo C, Boenzi S, Carducci C, et al. Vigabatrin improves paroxysmal dystonia in succinic semialdehyde dehydrogenase deficiency. Neurology. 2007;68(16):1320–1.
pubmed: 17438226
doi: 10.1212/01.wnl.0000259537.54082.6d
Iwata Y, Irie S, Uchida H, Suzuki T, Watanabe K, Iwashita S, et al. Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial. J Neurol Sci. 2012;315(1–2):137–40.
pubmed: 22285275
doi: 10.1016/j.jns.2011.12.010
Velasco PEB, Goiburu JAZ, Pinel RS. Restless legs syndrome induced by zonisamide. Mov Disord. 2007;22(10):1517–8.
pubmed: 17486608
doi: 10.1002/mds.21449
Handforth A, Martin FC, Kang GA, Vanek Z. Zonisamide for essential tremor: an evaluator-blinded study. Mov Disord. 2009;24(3):437–40.
pubmed: 19117357
doi: 10.1002/mds.22418
Suda S, Yamazaki M, Katsura K, Fukuchi T, Kaneko N, Ueda M, et al. Dramatic response to zonisamide of post-subarachnoid hemorrhage Holmes’ tremor. J Neurol. 2012;259(1):185–7.
pubmed: 21647726
doi: 10.1007/s00415-011-6127-5